ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 112 citations in OpenAlex.
- Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.The Journal of clinical investigation · 2014Trial
- Pilot analysis of cytokines levels in stored granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell concentrates.Transfusion · 2010Trial
- CD8Evidence-based complementary and alternative medicine : eCAM · 2023Article
- TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine.Nature communications · 2022Article
- Review
- Review
- Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner.Cellular & molecular immunology · 2021Article
- Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.Frontiers in immunology · 2021Review
- Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.The Journal of clinical investigation · 2020Review
- Review
- Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells.Cancers · 2019Review
- Cancer vaccine strategies: translation from mice to human clinical trials.Cancer immunology, immunotherapy : CII · 2018Review
- Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?Oncogene · 2018Review
- Review
- Cancer vaccines: translation from mice to human clinical trials.Current opinion in immunology · 2018Review
- Tissue-Specific Roles of NKT Cells in Tumor Immunity.Frontiers in immunology · 2018Review
- Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity.Frontiers in immunology · 2018Review
- Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice.European journal of immunology · 2017Article
- Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Nature immunology · 2017Article
- Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8Oncology letters · 2017Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeTransforming growth factor-beta (TGF-beta) is an immunosuppressive cytokine, having direct suppressive activity against conventional CD4(+) and CD8(+)T cells and natural killer cells, thereby inhibiting tumor immunosurveillance. Here, we investigated possible synergy between anti-TGF-beta (1D11) and a peptide vaccine on induction of antitumor immunity, and the mechanisms accounting for synergistic efficacy. EXPERIMENTAL
designThe effect of combination treatment with a peptide vaccine and anti-TGF-beta was examined in a subcutaneous TC1 tumor model, as well as the mechanisms of protection induced by this treatment.
resultsAnti-TGF-beta significantly and synergistically improved vaccine efficacy as measured by reduction in primary tumor growth, although anti-TGF-beta alone had no impact. The number of tumor antigen-specific CTL with high functional avidity as measured by IFN-gamma production and lytic activity was significantly increased in vaccinated mice by TGF-beta neutralization. Although TGF-beta is known to play a critical role in CD4(+)Foxp3(+) Treg cells, Treg depletion/suppression by an anti-CD25 monoclonal antibody (PC61) before tumor challenge did not enhance vaccine efficacy, and adding anti-TGF-beta did not affect Treg numbers in lymph nodes or tumors or their function. Also, TGF-beta neutralization had no effect on interleukin-17-producing T cells, which are induced by TGF-beta and interleukin-6. Absence of type II NKT cells, which induce myeloid cells to produce TGF-beta, was not sufficient to eliminate all sources of suppressive TGF-beta. Finally, the synergistic protection induced by anti-TGF-beta vaccine augmentation was mediated by CD8(+) T cells since anti-CD8 treatment completely abrogated the effect.
conclusionsThese results suggest that TGF-beta blockade may be useful for enhancing cancer vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.